You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾-B(06185.HK):吸入用新冠疫苗安全性良好 誘導更高中和抗體水平
據《澎湃新聞》報道,康希諾生物-B(06185.HK)發布消息稱,近期,國際頂尖醫學期刊《柳葉刀-呼吸病學》發表了有關康希諾生物吸入用新冠疫苗的最新研究成果。 研究結果顯示,序貫加強康希諾吸入用新冠疫苗安全性良好,總不良反應發生率低於滅活疫苗同源加強,無嚴重不良反應發生,但可以比滅活疫苗同源加強誘導出更高水平的中和抗體水平。 免疫原性結果顯示,以康希諾吸入用新冠疫苗序貫加強免疫28天後,兩個劑量組針對原始毒株的中和抗體水平分別是滅活同源加強組的18.4至26.4倍。同時,序貫加強康希諾吸入用新冠疫苗對Delta突變株也具有高水平的交叉保護,中和抗體水平是滅活疫苗的18.1至24倍。 康希諾生物介紹,目前,吸入用新冠疫苗已經完成疫苗初免和序貫免疫相關的一期、二期臨床試驗。安全性方面,研發團隊也已經積累了上萬例的臨床數據,正在開展三期臨床研究。下一步將積極推動吸入用新冠疫苗在國內和海外的緊急使用或者附條件上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account